Modest Growth, Less-Than-Modest Stock Drop

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Everyone seems to be focused on Dendreon's (Nasdaq: DNDN  ) continued guidance of "modest quarter-over-quarter growth" for its prostate cancer treatment, Provenge. We still don't have a firm definition of what management means, but based on yesterday's conference call, at least we know it's somewhere between 0% and the almost 30% growth we saw in the third quarter. Not too helpful.

The number investors really should be focused on is $106 million. That's the amount of cash the company burned through last quarter. With only $568 million, the runway is getting shorter.

Cost of goods seems to be the main culprit for the cash burn. With three manufacturing facilities up and running at less than full capacity, Dendreon's gross profit margin -- a measly 14% -- looks more like a discount retailer than a brand-name drugmaker. By comparison, here are the gross margins of a few companies with recent drug launches.


Most Recent Calendar Quarter Reported

Gross Margins

Dendreon Q3 2011 14.5%
Vertex Pharmaceuticals (Nasdaq: VRTX  ) Q3 2011 94.2%
Acorda Therapeutics (Nasdaq: ACOR  ) Q2 2011 81.5%
AVANIR Pharmaceuticals (Nasdaq: AVNR  ) Q2 2011 95.2%
Human Genome Sciences (Nasdaq: HGSI  ) Q3 2011 59.7%*

Source: S&P Capital IQ.
*Gross margin on Benlysta sales only.

The good news is that there are a lot of fixed costs in Dendreon's number because of the way Provenge is made individually for each patient. As the company increases sales, it should be able to dramatically increase gross margins.

Dendreon has said it needs sales of around $500 million annually to be cash flow positive, and it's currently at a run rate of about $250 million. To get there in five quarters -- the amount of cash left on hand -- it would need quarter-over-quarter growth of about 15%, which seems reasonable to me but may or may not be management's definition of "modest."

Of course, it doesn't really need to get to $500 million that quickly because the burn rate will go down as the sales ramp up.

Long-term investors don't really need to worry about the haircut the stock got today or the definition of "modest quarter-over-quarter growth." As long as the company can get to cash flow positive, the long-term returns will be based on Provenge's peak sales.

Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Dendreon. Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (2) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 04, 2011, at 4:33 AM, shebuks wrote:


    Dr Mitch already talk about Modest Growth in September conference

    Why the market react yesterday like this is new news?


  • Report this Comment On November 04, 2011, at 6:21 PM, TMFBiologyFool wrote:

    There's no definition of modest. The company grew by 30% QOQ from Q2 to Q3. If everyone was assuming that's the definition of modest (which apparently it isn't) then continued guidance is below investors expectations.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1583614, ~/Articles/ArticleHandler.aspx, 10/22/2016 9:42:52 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 12 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
ACOR $20.10 Down -0.10 -0.50%
Acorda Therapeutic… CAPS Rating: ****
AVNR.DL $0.00 Down +0.00 +0.00%
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
HGSI.DL $0.00 Down +0.00 +0.00%
Human Genome Scien… CAPS Rating: **
VRTX $80.76 Down -2.16 -2.60%
Vertex Pharmaceuti… CAPS Rating: ****